Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib, Dalpiciclib, and Letrozole in Stage II-III Triple-Positive Breast Cancer
NCT04486911Phase 2Active, not recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Jul 2020
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib, dalpiciclib in breast cancer, sponsored by Shengjing Hospital of China Medical University. Started Jul 2020; status: active, not recruiting.
02
Drugs
pyrotinibdalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04486911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486911.